Nyrada Inc (ASX:NYR) Advances Phase I Clinical Trial to Third Cohort
Clinical Trial Progress
Nyrada Inc (ASX:NYR) announced that its Phase I clinical trial has been approved by the Safety Review Committee to proceed to the third cohort. Recruitment for the next group is currently underway, with final trial readouts expected in the third quarter of calendar year 2025.
Lead Drug Candidate NYR-BI03
The company is developing NYR-BI03, a first-in-class Transient Receptor Potential Canonical (TRPC) ion channel inhibitor aimed at neuroprotection and cardioprotection. Previous preclinical studies have demonstrated significant neuroprotective and cardioprotective effects.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
